玻璃体切除治疗合并脉络膜脱离的孔源性视网膜脱离

目的研究玻璃体切除对合并脉络膜脱离的孔源性视网膜脱离的治疗作用。方法对连续治疗的12例合并有脉络膜脱离的孔源性视网膜脱离患眼,进行玻璃体切除联合长效气体或硅油填充治疗,所有病人术前术后均用激素治疗,对视网膜的复位率进行评价。结果平均随访10.42个月,单次手术视网膜解剖复位率为91.67%（11/12）。再次手术后视网膜解剖复位率为100%。结论玻璃体切除术是治疗合并脉络膜脱离的孔源性视网膜脱离的有效方法。     

合并脉络膜脱离的孔源性视网膜脱离的临床疗效分析

目的探讨合并脉络膜脱离的孔源性视网膜脱离患者的手术治疗方法。方法收集2002年1月至2004年6月治疗的125例(125眼)合并脉络膜脱离的孔源性视网膜脱离患者的临床资料,随访6至35个月,平均(23.4±10.2)月,分析手术方法与疗效的关系。结果本组患者巩膜扣带术的复位率为82.8%(24/29),再次手术率为27.6%(8/29);玻璃体切除术的复位率为94.8%(90/96),再次手术率38.5%(37/96)。125例最终视网膜解剖复位率为95.2%(119/125)。结论玻璃体切除术是治疗合并脉络膜脱离的孔源性视网膜脱离的有效方法。对脉络膜脱离程度较轻,PVRB、PVRC1级患者也可行巩膜扣带术。     

玻璃体切除联合曲安奈德玻璃体腔注射治疗孔源性视网膜脱离

目的 探讨玻璃体切除联合曲安奈德(TA)玻璃体腔内注射治疗合并脉络膜脱离的孔源性视网膜脱离的临床疗效和安全性.方法 观察采用玻璃体切除联合曲安奈德玻璃体腔内注射治疗合并脉络膜脱离的孔源性视网膜脱离15例患者(15眼),术后不再全身应用糖皮质激素,仅给予激素眼液点眼.结果 术后随访时间6～30个月,平均(19±9.5)个月.一次手术视网膜复位率100%.术后3个月硅油取出后,2例视网膜脱离复发,1例再次剥膜充填硅油后视网膜复位;另1例放弃治疗.视网膜总复位率为93.3%(14/15).术后并发症包括:4例术后眼压升高,均局部用药控制,5例出现晶状体后囊下皮质局限性混浊.结论 玻璃体切除联合(TA)玻璃体腔内注射治疗合并脉络膜脱离的孔源性视网膜脱离,可以明显减轻术后葡萄膜炎症反应,从而减少PVR的发生,显著提高手术的成功率.     

合并脉络膜脱离的孔源性视网膜脱离临床特点及手术疗效分析

目的:分析合并脉络膜脱离的裂孔性视网膜脱离的临床特点及手术治疗效果。方法:合并脉络膜脱离的裂孔性视网膜脱离患者64例64眼,26例行巩膜扣带术,38例行玻璃体视网膜手术,术中均不行巩膜外冷凝,观察眼部表现及手术复位率等情况,分析合并脉络膜脱离的裂孔性视网膜脱离临床特点。结果:本组病例>-6.00D高度近视占总病例数的41%。64例合并脉络膜脱离的孔源性视网膜脱离均有葡萄膜炎反应,眼压2.00～8.00mmHg;26例行巩膜扣带术,19例视网膜复位,复位率73%,行玻璃体视网膜手术38例,32例视网膜复位,一次手术复位率84%。结论:合并脉络膜脱离的孔源性视网膜脱离高度近视眼、人工晶状体眼及无晶状体眼多发,视网膜光凝替代术中巩膜外冷凝可能提高视网膜复位率及减少术后复发率。     

玻璃体切除术治疗合并脉络膜脱离的孔源性视网膜脱离18例

目的：探讨玻璃体切除术治疗孔源性视网膜脱离并发脉络膜脱离的方法和疗效。方法：18例18眼并发脉络膜脱离的孔源性视网膜脱离,行玻璃体切除术治疗,术后观察视力、视网膜复位情况及手术并发症等,随访2～6(平均3．3)mo。结果：在18眼中13眼(72％)术后视网膜复位,大部分视力均有不同程度的提高;5眼视网膜未复位,其中3眼经再手术后复位,2眼眼球萎缩,未再手术。手术并发症主要有术后葡萄膜炎、玻璃体积血、术后高眼压等。结论：及时的玻璃体手术治疗合并脉络膜脱离的孔源性视网膜脱离,大多数视网膜能够获得复位,部分恢复视功能。     

玻璃体切除术前应用糖皮质激素治疗脉络膜脱离型视网膜脱离的效果分析

目的 研究术前糖皮质激素的不同应用途径对孔源性视网膜脱离伴有脉络膜脱离玻璃体切除术后解剖复位的影响。设计 回顾性病例系列。研究对象 北京同仁医院就诊的伴有脉络膜脱离的孔源性视网膜脱离患者155例（155眼）。方法 根据术前糖皮质激素使用情况分为4个组：未应用糖皮质激素（A组）43眼;口服糖皮质激素（B组）42眼;球旁注射糖皮质激素组（C组）32眼;玻璃体注射曲安奈德组（D组）38眼。所有患者均为首次行玻璃体切除手术。观察术后6个月视网膜解剖复位的情况。主要指标 首次玻璃体切除术后视网膜复位情况。结果 首次玻璃体切除术后,A组视网膜复位27眼,手术治愈率62.79%;B组视网膜复位37眼,手术治愈率88.10%;C组视网膜复位29眼,手术治愈率90.63%;D组视网膜复位34眼,手术治愈率89.47%。A组术后视网膜复位率与其他组比较均有统计学意义（P均<0.05）;B、C、D三组间比较无明显统计学意义（P>0.05）。结论 对于伴有脉络膜脱离的孔源性视网膜脱离,术前应用糖皮质激素可以提高术后视网膜复位率;口服、球旁和玻璃体注射不同糖皮质激素应用方式,对于玻璃体切除术后视网膜复位率无明显差异,可根据患者全身及局部情况进行选择。     

玻璃体切除联合曲安奈德治疗视网膜脱离合并脉络膜脱离的临床观察

目的 评价玻璃体切除联合曲安奈德治疗视网膜脱离合并脉络膜脱离的临床效果.方法 视网膜脱离合并脉络膜脱离32例(32眼).发现合并裂孔者23例.行玻璃体切除术,术中将曲安奈德注射于玻璃体腔,术后随访3～24个月,观察术后视网膜复位率,视力恢复情况.结果 术后随访3～24个月,复位率为81.2%,术后视力均有不同程度提高,矫正视力最高为0.5,最低0.03,平均矫正视力0.2.结论 玻璃体切除联合曲安奈德玻璃体腔注射治疗视网膜脱离合并脉络膜脱离,阻止增生性玻璃体视网膜病变的再生,提高了视网膜复位率.     

玻璃体切除治疗合并脉络膜脱离的黄斑裂孔性视网膜脱离疗效分析

目的探讨玻璃体切除治疗合并脉络膜脱离黄斑裂孔性视网膜脱离的临床疗效。方法对确诊为合并脉络膜脱离黄斑裂孔性视网膜脱离的48例（48只眼）随机分为应用糖皮质激素联合玻璃体切除手术组和直接行玻璃体切除手术组。对比术后视力变化、眼压、脉络膜脱离复位率、视网膜脱离复位率、黄斑裂孔状态及术后并发症等。结果经一次手术38只眼视网膜脉络膜完全复位，平均视力较术前有明显改善（P〈0．05）。术后并发症包括一过性眼压升高、晶状体混浊加剧及复位不成功等。结论对于合并脉络膜脱离的黄斑裂孔性视网膜脱离，无论术前是否应用激素，术后疗效视功能相近。术前应用糖皮质激素的必要性值得探讨。及时采取玻璃体手术是一种有效的治疗手段。     

玻璃体切割术治疗视网膜脱离合并脉络膜脱离

目的探讨玻璃体切割术治疗视网膜脱离合并脉络膜脱离的临床疗效及适应证.方法对23例(23眼)视网膜脱离合并脉络膜脱离的患者,术前7 d即开始口服强的松,采用标准平坦部三切口玻璃体切割及眼内填充(C3F8或硅油),酌情联合巩膜扣带术,术后随访6～12个月.结果术中新发现裂孔 5个(21.74%);术后6个月,视网膜完全复位20眼(86.96%),部分复位2眼(8.70%),未复位1眼(4.35%);术后视力有不同程度的提高,其中0.1以上为5眼(21.74%);术后并发症较少,增生性玻璃体视网膜病变(proliferativevitreore tinopathy,PVR)的发生率较低.结论对眼内增殖明显,视网膜裂孔位于大范围脉络膜脱离区或术前未发现裂孔的视网膜脱离合并脉络膜脱离,玻璃体切割术是可以优先考虑的术式.     

曲安奈德联合眼压升高法治疗脉络膜脱离型视网膜脱离的初步探讨

目的 探讨曲安奈德玻璃体腔注射联合眼压升高法治疗脉络膜脱离型孔源性视网膜脱离的疗效.方法 11例(11只眼)合并脉络膜脱离的孔源性视网膜脱离,予玻璃体腔注射曲安奈德及平衡盐溶液或50%C3,F8,观察眼压、脉络膜脱离及视网膜脱离复位情况.结果 治疗后11只眼眼压回升,10只眼7 d内脉络膜脱离复位,1只眼治疗后第8天复位;视网膜复位手术一次性成功10只眼(90.9%),1只眼经二次手术视网膜脱离复位.随访3至12个月,11只眼视网膜复位.结论 曲安奈德玻璃体腔注射联合眼压升高法能迅速、安全、有效地治疗脉络膜脱离型视网膜脱离,简化手术过程,提高脉络膜脱离型视网膜脱离的手术成功率.     

A comparison of the anatomic successes of primary vitrectomy for rhegmatogenous retinal detachment with superior and inferior breaks

Purpose: To compare the anatomic success between repair of rhegmatogenous retinal detachment (RRD) with superior breaks and repair of RRD with inferior breaks, by performing primary vitrectomy and using similar techniques and the same gas. Methods: Eighty‐two consecutive eyes of 80 patients with RRD were included in this retrospective comparative study. The eyes were divided into two groups according to the location of the breaks: superior (n = 62) and inferior (n = 20). All the patients underwent a standard, 3‐port, 20‐gauge pars plana vitrectomy with 20% sulphur hexafluoride gas tamponade performed by the same surgeon. The main outcome measured was the primary anatomic reattachment at 3 months after surgery. Results: The primary anatomic success rate in the inferior group was significantly lower than that in the superior group (80% versus 98%, p = 0.012). In the inferior group, the primary anatomic success rate in patients whose symptoms lasted for more than 2 weeks was significantly lower than that in others (5/9 versus 11/11, p = 0.026). Multivariate logistic regression analysis identified inferior break as the only independent risk factor for redetachment (odds ratio, 11.88; p = 0.034). Conclusion: The anatomic success of primary vitrectomy for RRD with inferior breaks is lower than that for RRD with superior breaks. In particular, the duration of symptoms longer than 2 weeks is associated with a worse outcome in patients who had RRD with inferior breaks.     

高度近视黄斑裂孔性视网膜脱离合并脉络膜脱离的相关因素分析

目的 探讨高度近视黄斑裂孔性视网膜脱离合并脉络膜脱离的相关危险因素,总结其临床特点及治疗方法.方法 连续收集合并脉络膜脱离的高度近视黄斑裂孔性视网膜脱离的病例10例(A组),并以同一时期不伴脉络膜脱离的高度近视黄斑裂孔性视网膜脱离病例12例为对照(B组),对比两组发病年龄、病程、术前屈光度、眼轴、眼压、视网膜脱离范围以及术后视网膜复位、视功能恢复等情况.结果 A组发病年龄大、近视度数高、眼压低、视网膜脱离范围大,与B组相比差异有统计学意义(P<0.05),其中眼压差异显著(P<0.01);两组的一次玻璃体切割手术视网膜复位率相近,A组为80%,B组为83%,但A组术后视力≥0.02的比例低(P=0.048).结论 高度近视黄斑裂孑L性视网膜脱离一旦合并脉络膜脱离常伴有年龄大、病程长、近视度数高、视网膜脱离广泛和显著低眼压等特点.适时采用玻璃体切割合并硅油填充术可达到与不合并脉络膜脱离组相近的视网膜复位率,但视力预后仍较差.     

Vitrectomy, lensectomy and silicone oil tamponade in the management of retinal detachment associated with choroidal detachment

AIM:To report the results of combined vitrectomy, lensectomy and silicone oil (SO) tamponade in treating primary rhegmatogenous retinal detachment (RRD) associated with choroidal detachment (CD).METHODS:A retrospective, consecutive and case series study of 21 subjects with concurrent RRD associated with CD was conducted. All subjects underwent a standard three-port 20G pars plana vitrectomy (PPV) with lensectomy and silicone oil tamponade. Mean follow-up time was 8 months (rang from 4 to 19 months). The primary and final anatomic success rate, visual acuity and final intraocular pressure(IOP) were recorded and analyzed.RESULTS:Of 21 subjects, 8 were women and 13 were men. Age at presentation ranged from 22 to 75 years (mean 57.4 years). The presenting vision ranged from light perception to 0.15. The initial IOP ranged from 3mmHg to 12mmHg (mean 6.2mmHg). All eyes were phakic except one pseudophakic. No intraocular lens was implanted during the primary surgical intervention. Fifteen of 21 (71.4%) eyes had retina reattached after one operation. Six eyes had recurrent inferior retinal detachment due to proliferation. Five of them were successfully reattached after one or more additional operations. Mean IOP at final follow-up was 15.2mmHg (range from 8mmHg to 20mmHg). One case declined for further operation. The final reattachment rate was 95.2%. Visual acuity improved in 19 (90.5%) eyes, was unchanged in 1 (4.8%) eye and decreased in 1 (4.8%) eye.CONCLUSION:Combination of vitrectomy, lensectomy and silicone tamponade is an effective method in treating RRD associated with CD, reducing the incidence of postoperative hypotony.     

23G微创玻璃体切割术在孔源性视网膜脱离中的应用

目的：评估23G经结膜无缝线玻璃体切割手术治疗孔源性视网膜脱离的安全性及有效性。 方法：前瞻性选择2010-03/2011-06共26例26眼不伴有严重增生性病变的孔源性视网膜脱离病历,均行23G切割手术。记录术前、术后的最佳矫正视力（BCVA）、眼压,术中及术后并发症。 结果：一次性复位视网膜21例（81%）,最终复位视网膜25例（96%）。术后3mo最佳矫正视力较术前提高21例（80%）,不变3例（12%）,下降2例（8%）。术后1d眼压较术前下降,此差异有统计学意义（P<0.01）。低眼压（≤6mmHg）2例,持续2wk,但未发生脉络膜脱离。 结论：23G手术治疗孔源性视网膜脱离解剖复位率满意,术后视力改善明显。但23G微创手术的优势并没有在孔源性视网膜脱离的手术中得到充分体现,反而要面临更高的手术失败的风险。     

曲安奈德玻璃体腔内注射辅助治疗脉络膜脱离型视网膜脱离

目的:评价玻璃体手术前1d玻璃体腔内注射曲安奈德治疗脉络膜脱离型视网膜脱离的疗效和安全性。方法:对28例(28眼)脉络膜脱离型视网膜脱离患者于玻璃体手术前1d玻璃体腔注射曲安奈德混悬液0.1mL(4mg)。手术方式为巩膜环扎联合玻璃体切除,术后C3F8或硅油充填。24眼随访6～17(平均8.9)mo。结果:28眼注射曲安奈德后葡萄膜炎症减轻。24眼单次手术视网膜解剖复位率87.5%(21/24)。结论:在玻璃体手术治疗脉络膜脱离型视网膜脱离前1d玻璃体注射曲安奈德使手术难度降低,提高了视网膜复位率。     

玻璃体切除联合空气填充治疗下方裂孔的孔源性视网膜脱离的短期疗效

目的 尝试应用玻璃体切除联合玻璃体腔空气填充治疗下方裂孔的孔源性视网膜脱离（RRD），观察其可行性。设计 回顾性病例系列。研究对象 2017年6月至2020年10月间在南京爱尔眼科医院接受23G经睫状体平坦部三通道行微创玻璃体切除术（PPV）联合玻璃体腔无菌空气填充治疗的下方裂孔的RRD患者45例（45眼）。方法 所有患者均行23G PPV手术，玻璃体切除后玻璃体腔单纯无菌空气填充。患者术前及术后5天、3周、3个月均行矫正视力、非接触眼压、裂隙灯检查、裂隙灯下眼底镜检查、广角眼底照相、相干光断层扫描（OCT）、眼科AB超、IOL-Master测眼轴长度等检查。观察术后视网膜一期复位率、最佳矫正视力（BCVA）、眼压及并发症情况。主要指标 视网膜一期复位率、BCVA、眼压及并发症情况。结果 1例患者在术后2个月时因局限性视网膜脱离行巩膜外加压术复位，余44例均一期复位，复位率97.8%，术后随访3个月均未发现再脱离。术前LogMAR BCVA为1.82±0.83，术后5天、3周，3个月分别为0.71±0.34、0.59±0.32、0.56±0.30，均较术前有显著提高（P均＜0.001）。随访期内，仅术后第1天有2例患者眼压升高，其余患者均未发现眼压升高及其他并发症发生。结论 玻璃体切除联合玻璃体腔空气填充治疗下方孔源性视网膜脱离是一种可选择的经济有效的方法。（眼科，2021, 30： 217-221）     

Primary vitrectomy for combined rhegmatogenous retinal detachment and choroidal detachment with or without oral corticosteroids: a pilot study

PURPOSE: The occurrence of choroidal detachment (CD) in eyes with primary rhegmatogenous retinal detachment (RRD) is relatively uncommon (2%-4.5%). Recent reports suggest that primary vitrectomy yields better anatomic success than scleral buckling. However, for these inflamed eyes with low intraocular pressure, the influence of preoperative oral steroids on reattachment rates has not been elucidated yet. METHODS: Twenty eyes with combined RRD and CD that underwent primary vitrectomy were randomized to receive oral steroids (for 1 week) or no oral steroids before surgery. RESULTS: Preoperative clinical data such as mean age, lens status, Snellen visual acuity, duration of macular detachment, CD (size and extent), and retinal detachment characteristics (e.g., extent, number of retinal breaks, atrophic or tractional retinal break, size of retinal break, and location of retinal break) were similarly distributed in both groups. Single-operation anatomic success was 81.8% (9/11) among those patients who received preoperative oral steroids and was 66.7% (6/9) among those who did not receive preoperative oral steroids. After reoperation, anatomic success was 100% in both groups. The mean follow-up was 20.1 months. CONCLUSION: The results suggest that administration of oral steroids before primary vitrectomy in eyes with combined RRD and CD improves reattachment rates.     

超高度近视合并孔源性视网膜脱离手术治疗的临床分析

目的：回顾分析超高度近视合并孔源性视网膜脱离(rhegmatogenous retinal detachment,RRD)的手术方式、手术效果、术后并发症及处理方法。
　　方法：选择2011-01-01/2016-01-01于我院就诊的超高度近视合并RRD的患者47例47眼,并于我院行巩膜外加压术,玻璃体切除( pars plana vitrectomy,PPV)联合硅油填充术,或玻璃体腔注气术,回顾分析术后6 mo内患者的BCVA、眼压、视网膜复位情况、裂孔闭合程度及术后并发症。
　　结果：患者术后6 mo时行PPV联合硅油填充的患者视力提高者24眼(71%);单纯行巩膜外加压术的患者视力提高8眼(73%)。统计学检验可见手术治疗能明显改善患者视力,尤其PPV联合硅油填充,但单纯行巩膜外加压术患者视力在本研究中经统计学检验显示无明显意义。PPV联合硅油填充的患者术后高眼压及复视等术后并发症较其他术式更多。
　　结论：超高度近视合并孔源性视网膜脱离的患者需要及时行手术治疗,对术者临床经验及手术要求极高,需要术者根据视网膜裂孔的大小、位置及视网膜脱离范围选择不同的术式,及时恰当处理术后并发症,以争取患者术后裂孔最大程度的闭合、提高视网膜复位率及视功能,提高患者生活质量。     

Primary vitrectomy for rhegmatogenous retinal detachment associated with choroidal detachment

Objective

This study aimed to report the success rate of primary vitrectomy, scleral buckling, and oral steroids in eyes with combined rhegmatogenous retinal detachment (RRD) and choroidal detachment (CD) and to compare these results with those reported in the literature for similar cases managed by scleral buckling alone.

Design

Consecutive case series.

Participants

Twenty-one eyes of 21 consecutive patients with primary RRD associated with CD were examined.

Intervention

All patients were treated with systemic corticosteroids before surgery. Pars plana vitrectomy with scleral buckling or encircling or both were performed.

Main outcome measures

Retinal reattachment rate and resolution of choroidal detachment were measured.

Results

At mean follow-up of 11.4 months, retinal reattachment was attained in 19 eyes (90.5%) compared to less than 53% reported in the literature for scleral buckling alone. With preoperative oral steroids, choroidal detachment regressed completely in 13 eyes (61.9%). In the remaining eyes with persistent choroidal detachment, suprachoroidal fluid was drained during vitrectomy.

Conclusion

Aggressive treatment with oral steroids followed by pars plana vitrectomy and scleral buckling or encircling is recommended instead of scleral buckling alone in the management of combined primary rhegmatogenous retinal detachment and choroidal detachment.